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Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour in humans and is highly resistant to
current treatment modalities. We have explored the combined treatment of the endoplasmic reticulum (ER) stress-
inducing agent 2,5-dimethyl-celecoxib (DMC) and TNF-related apoptosis-inducing ligand (TRAIL WT) or the DR5-specific
TRAIL D269H/E195R variant as a potential new strategy to eradicate GBM cells using TRAIL-resistant and -sensitive GBM
cells. GBM cell lines were investigated for their sensitivity to TRAIL, DMC and combination of both agents. Cell viability
was measured by MTS assay and apoptosis was assessed by Annexin V/PI and acridine orange staining. Caspase
activation and protein expression levels were analysed with Western blotting. Death Receptor (DR) cell surface expression
levels were quantified by flow cytometry. DR5 expression was increased in U87 cells by ectopic expression using a
retroviral plasmid and survivin expression was silenced using specific siRNAs. We demonstrate that A172 expresses
mainly DR5 on the cell surface and that these cells show increased sensitivity for the DR5-specific rhTRAIL D269H/
E195R variant. In contrast, U87 cells show low DR cell surface levels and is insensitive via both DR4 and DR5. We
determined that DMC treatment displays a dose-dependent reduction in cell viability against a number of GBM cells,
associated with ER stress induction, as shown by the up-regulation of glucose-regulated protein 78 (GRP78) and
CCAAT/-enhancer-binding protein homologous protein (CHOP) in A172 and U87 cells. The dramatic decrease in cell
viability is not accompanied by a correspondent increase in Annexin V/PI or caspase activation typically seen in
apoptotic or/and necrotic cells within 24h of treatment. Although DMC did not affect DR5 expression in the GBM cells,
it increased TRAIL-induced caspase-8 activation in both TRAIL-sensitive and -resistant cells, indicating that DMC
potentiates initiator caspase activation in these cells. In A172 cells, sub-toxic concentrations of DMC greatly potentiated
TRAIL-induced apoptosis. Furthermore, DMC strongly reduced survivin expression in A172 and U87 cells and silencing
of this anti-apoptotic protein partially sensitized cells to TRAIL-induced apoptosis. Our findings corroborate that DMC is
a promising agent against GBM, and uncovers a potential synergistic cooperation with TRAIL in this highly malignant
cancer.
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Glioblastoma multiforme (GBM) has been classified as a
WHO grade IV glioma. This type of tumour is the most
common and aggressive of the glial tumours. Despite the
available treatment modalities, consisting of surgical
resection followed by a combination of radiation and* Correspondence: W.J.Quax@rug.nl
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reproduction in any medium, provided the origchemotherapy, the median survival rate ranges from 12–
15 months (Stupp et al. 2005). To improve the prognosis
of GBM patients, novel therapies are therefore required.
TNF-related apoptosis-inducing ligand (TRAIL), a
member of the TNF superfamily, has previously been
shown to be a promising anti-cancer therapeutic agent
(Wiley et al. 1995; Pitti et al. 1996) for its ability to in-
duce apoptosis in a variety of tumour cells, without af-
fecting normal cells (Ashkenazi et al. 1999; Lawrence
et al. 2001). Trimeric recombinant human TRAIL
(rhTRAIL) is able to induce apoptosis upon binding to. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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ceptor 5 (DR5, TRAIL-R2). TRAIL receptor-specific
apoptosis-inducing variants have previously been gener-
ated, displaying enhanced affinity for either DR4 or DR5,
resulting in more potent apoptosis induction in several
tumour cells (van der Sloot et al. 2006; Reis et al. 2010).
Binding of TRAIL to its cognate death receptors triggers
the establishment of the death-inducing signalling com-
plex (DISC), composed of FAS-associated death domain
(FADD) and pro-caspase-8. Upon DISC formation, the
initiator pro-caspase-8 is processed into active caspase-8,
which is able to either directly cleave effector caspases-3
and −7, or cleave Bid into truncated Bid (tBid). The latter
results in the release of mitochondrial factors, including
cytochrome c, subsequently leading to caspase-9 cleavage
and further activation of effector caspases, resulting in ir-
reversible apoptosis (Budihardjo et al. 1999). In general,
GBM cells have been found to be highly resistant to
TRAIL-induced apoptosis due to a variety of reasons, such
as moderate to low expression of DR4 and DR5 (Knight
et al. 2001; Kuijlen et al. 2006), the up-regulation of the
anti-apoptotic proteins c-Flip, Bcl-2 and survivin (Knight
et al. 2001; Kouri et al. 2012; Song et al. 2003; Xie et al.
2006; Fulda et al. 2002), or the down-regulation of critical
pro-apoptotic proteins such as caspase-8 and Bak (Knight
et al. 2001; Song et al. 2003; Capper et al. 2009; Qi et al.
2011).
Recently, an increasing number of reports have shown
the therapeutic relevance of inducers of endoplasmic
reticulum (ER) stress in cancer, also as sensitizers for
TRAIL-based therapies (Chen et al. 2007; Zhou et al.
2013; Yoon et al. 2013; Martin-Perez et al. 2012; Kim
et al. 2011; Tian et al. 2011; Gaiser et al. 2008). ER stress
can be triggered by alterations in normal ER function,
such as the accumulation of unfolded, misfolded or ex-
cessive proteins, imbalances of lipids or glycolipids, or
changes in the redox or ionic conditions within the ER
lumen (Lee 2001, Boyce & Yuan 2006, Wu & Kaufman
2006). The ER stress inducer 2,5-dimethyl-celecoxib
(DMC) is an analogue of the cyclooxygenase-2 (COX-2)-
selective non-steroidal anti-inflammatory drug (NSAID)
celecoxib. At the molecular level, DMC lacks the COX-2
inhibitory function present in celecoxib, whereas the ER
stress-activating potential is enhanced by DMC (Pyrko
et al. 2007; Chuang et al. 2008). DMC has also been
shown to block cell proliferation in several tumour cell
culture models (Chuang et al. 2008; Pyrko et al. 2006)
and demonstrated anti-tumorigenic activity in vivo
(Pyrko et al. 2006). ER stress appears to be initiated
within seconds after the addition of DMC to cultured
cells, through the inhibition of the sarcoplasmic/ER cal-
cium ATPase (SERCA) (Pyrko et al. 2007; Johnson et al.
2002; Tanaka et al. 2005). Consequently, an ER stress re-
sponse (ESR) is triggered, which is characterized by theup-regulation of ER molecular chaperones, including
the pro-survival regulator glucose-regulated protein 78
(GRP78), therefore facilitating protein folding, transloca-
tion of polypeptides across the ER membrane, and the ac-
tivation of transmembrane ER stress sensors (Li & Lee
2006). Another ER stress indicator is the enhanced expres-
sion of the pro-apoptotic CCAAT/-enhancer-binding pro-
tein homologous protein (CHOP) (Kim et al. 2006;
Gorman et al. 2012; Siegelin 2012; Kardosh et al. 2008),
which has been found to up-regulate DR5 expression in
several cancer cell types (Chen et al. 2007; Zhou et al.
2013; Yoon et al. 2013; Martin-Perez et al. 2012; Kim et al.
2011; Tian et al. 2011; Lee et al. 2008). ER stress has also
been reported to down-regulate anti-apoptotic proteins,
including c-Flip (Chen et al. 2007; Zhou et al. 2013; Yoon
et al. 2013; Martin-Perez et al. 2012), Bcl-2 (Zhou et al.
2013; Lee et al. 2008; McCullough et al. 2001) and survivin
(Zhou et al. 2013; Gaiser et al. 2008). Moreover, prolonged
activation of ER stress can lead to the activation of
caspase-4 (Pyrko et al. 2007; Kardosh et al. 2008; Hitomi
et al. 2004) and −7 (Chuang et al. 2008; Kardosh et al.
2008) resulting in apoptosis.
In this study, we have explored the ability of DMC to
enhance TRAIL-induced apoptosis in GBM cells. We
demonstrate that A172, but not U87, is sensitive for
apoptosis induced by rhTRAIL, and especially for the
DR5-specific TRAIL variant D269H/E195R. DMC was
able to significantly reduce cell viability of several GBM
cell lines. We show that both sub-toxic and toxic doses
of DMC significantly enhance TRAIL-induced apoptosis
in A172 cells. Taken together, DMC in combination with
rhTRAIL appears to be a promising therapeutic ap-
proach for the treatment of a subset of GBM cells.
Results
A172 but not U87 cells are sensitive to TRAIL-induced
apoptosis primarily via DR5
Analysis of receptor expression by flow cytometry re-
vealed distinct differences in TRAIL receptor membrane
expression levels of A172 and U87 cells (Figure 1A).
While A172 cells express high levels of DR5, U87 cells
showed significantly lower levels of surface DR5. DR4
expression was found to be low in A172 and it was un-
detectable in U87. Low decoy receptor expression was
also detected in A172 cells and absent in U87 cells.
Since both A172 and U87 cells show distinct expression
profiles of DR5 on the membrane and low or absent ex-
pression of DR4, these cells were exposed to different
concentrations of rhTRAIL WT, and the previously de-
scribed DR4-selective variant (rhTRAIL 4C7) (Reis et al.
2010) and DR5-selective variant (rhTRAIL D269H/
E195R) (van der Sloot et al. 2006). A172 cells showed a
clear dose dependent sensitivity to rhTRAIL, when
treated with either rhTRAIL WT or rhTRAIL D269H/
Figure 1 A172 cells are sensitive to TRAIL-induced apoptosis in a dose-dependent manner. (A) Cell surface expression of the various TRAIL
receptors was determined on A172 and U87 cells using flow cytometry analysis and expressed as the Mean Fluorescence Intensity (MFI) ratio.
(B) Viability of A172 and U87 cells was assessed after treatment with various concentrations (0–1000 ng/ml) of rhTRAIL WT, 4C7 or D269H/E195R
for 24h as measured by MTS assays. (C) Western blot analysis of A172 and U87 cells treated with 0, 10 or 100 ng/ml rhTRAIL WT for 5h or 24h,
respectively. β-actin serves as a loading control. Error bars represent S.E.M. of three independent experiments.
van Roosmalen et al. SpringerPlus 2014, 3:495 Page 3 of 12
http://www.springerplus.com/content/3/1/495E195R, but was completely resistant to rhTRAIL 4C7.
The mutant D269H/E195R was more effective in redu-
cing cell viability in A172 when compared to rhTRAIL
WT. In contrast, U87 cells were highly resistant to all
rhTRAIL ligands (Figure 1B). Afterwards, Western blot
analysis was used to detect cleavage of caspases and
PARP after treatment with 10 (low) or 100 (moderately
high) ng/ml rhTRAIL WT. Since A172 cells proved to
be TRAIL-sensitive these cells were exposed to rhTRAIL
WT for 5h in order not to lose the cells due to massive
cell death. The TRAIL-resistant U87 cells were treated
for 24h. Accordingly, rhTRAIL WT exposure resulted in
clear cleavage of caspase-8, −9, −3 and PARP in A172
cells, whereas in U87 cells, even upon treatment with
100 ng/ml rhTRAIL WT, no activation of these apoptotic-
related proteins was observed (Figure 1C). We then tested
if the differential TRAIL-sensitivities observed in A172
and U87 could be explained by the differences at the level
of surface DR5 expression, with low levels of death recep-
tor expression in U87 cells causing the insensitivity to
both rhTRAIL WTand rhTRAIL D269H/E195R.Ectopic overexpression of DR5 in U87 cells does not
enhance TRAIL sensitivity
To investigate whether enhancement of DR5 expression
could trigger TRAIL-induced apoptosis, U87 cells were
transduced with either an empty retroviral vector (U87-
control) or a vector expressing DR5 (U87-DR5). This
vector contains the gene for tdTomato, allowing for the
isolation of transduced tdTomato-positive cells by FACS
sorting. DR5 expression levels were determined by flow
cytometry using TRAIL receptor-specific antibodies la-
belled with the Alexa Fluor 488 dye, since PE-labelled
antibodies would result in overlapping emission spectra
with tdTomato (Figure 2A). Notably, a large shift in
mean fluorescence intensity (MFI) levels was measured
when Alexa Fluor 488 was used compared to previous
results with the PE dye. Although the elevated surface
levels of DR5 in U87-DR5 cells is similar to the DR5 ex-
pression level observed in A172 cells, U87-DR5 cells did
not show enhanced sensitivity to rhTRAIL WT or
rhTRAIL D269H/E195R even at high concentrations of
rhTRAIL (up to 1000 ng/ml) (Figure 2B). These results
Figure 2 DR5 overexpression does not enhance TRAIL-induced apoptosis in U87 cells. (A) Flow cytometry analysis was performed on
U87-control and U87-DR5 cells to measure the cell surface expression of TRAIL receptors DR4 and DR5, expressed as the Mean Fluorescence Intensity
(MFI) ratio. A172 cells were used as a control. (B) Cell viability was assessed after 24h treatment with 0–1000 ng/ml rhTRAIL WT or D269H/E195R using
MTS assays. Presented data are representative for three independent experiments and mean cell viability levels ± S.E.M. are shown.
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to sensitize U87 cells to TRAIL-induced apoptosis.
DMC decreases cell viability of GBM cells and enhances
TRAIL-induced apoptosis in A172 cells
Next, we examined the potential of the ER stress inducer
DMC alone and in combination with TRAIL across
several GBM cell lines. We started by determining the
effect of DMC on the cell viability of GBM cells. As
shown in Figure 3A, DMC was able to efficiently pro-
mote reduction in cell viability as measured by MTS
in all the GBM cell lines studied. SNB75 cells showed
the highest sensitivity to DMC, whereas U251, A172
and U87 cells were almost equally sensitive to DMC
(Figure 3A).
To evaluate if the DMC effects observed in these cells
were correlated with the induction of apoptosis or ne-
crosis, A172 and U87 cells were treated with either a
sub-toxic (25 μM) or a moderate cytotoxic (50 μM) dose
of DMC for 24h and stained with Annexin V/PI, with
Annexin V positive cells representing the apoptotic frac-
tion. Figure 3B shows that the addition of a high concen-
tration of DMC alone resulted in a minor increase in
Annexin V positivity. In addition, after DMC treatment
the level of Annexin−/PI+ cells were comparable to un-
treated cells. Together with the results obtained using
MTS assays, these results suggest that treating cells with
concentrations up to 50 μM DMC did not result in
apoptosis or necrosis in these cells, contrasting with thesignificant reduction seen when using the MTS assay. In
order to assess if DMC induced ER stress, expression
levels of GRP78 and CHOP, two established markers of
ER stress, were examined. Consistent with the previously
described role of DMC in ER-stress induction, Western
blot analysis showed a clear up-regulation of GRP78 and
CHOP upon treatment with 50 μM of DMC, (Figure 3C).
Next, the effect of combined exposure to rhTRAIL WT
and 0, 25 or 50 μM of DMC was examined in these dif-
ferentially TRAIL-responsive GBM cell lines. In this
assay, A172 cells treated for 24h with 125 ng/mL
rhTRAIL without DMC showed already ~75% reduction
in cell viability (IC50: ~36 ng/ml), which was strongly en-
hanced after combination with DMC (25 μM: ~10%,
IC50: ~12 ng/ml and 50 μM: ~2%, IC50: ~1 ng/ml)
(Figure 4A). Notably, the cell viability of A172 cells was
reduced with approximately 86% using only 31.3 ng/ml
of rhTRAIL WT in combination with 25 μM of DMC,
when compared to TRAIL WT in combination with 0
μM DMC, where approximately 47% reduction in cell
viability could be attained. Therefore, TRAIL sensitivity
can be enhanced in A172 cells by co-treatment with
DMC. U87 cells remained TRAIL-resistant (0 μM: ~99%),
and although the single treatment with DMC was able to
lower the cell viability of U87 cells (25 μM: ~87%; 50 μM:
66%), no additive or synergistic effects could be found in
combination with rhTRAIL WT (Figure 4A). Since DMC
is an analogue of celecoxib, we further tested the sensitiv-
ity of these cell lines to celecoxib treatment. A172 and
Figure 3 DMC reduces cell viability and induces ER stress in GBM cell lines. (A) Cell viability was assessed in a panel of GBM cell lines after
24h exposure to 0–100 μM of DMC using a MTS assay. Error bars represent S.E.M. of three independent experiments. (B) A172 and U87 cells were
treated with 0, 25 or 50 μM DMC for 24h after which apoptosis induction was determined using Annexin V/PI using flow cytometry.
(C) Treatment of A172 and U87 cells with 0, 25 or 50 μM DMC for 24h resulted in a dose-dependent up-regulation of CHOP and GRP78 proteins
levels as showed by Western blotting. β-actin serves as a loading control. Presented data are representative for at least three independent
experiments and mean cell viability levels ± S.E.M. are shown.
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for both A172 and U87 (Additional file 1: Figure S1).
Next, DMC or celecoxib were tested side-by-side in com-
bination with rhTRAIL WT. Interestingly, the combin-
ation of TRAIL/DMC (IC50: ~57 μM) was shown to be
more effective than TRAIL/celecoxib (IC50: ~88 μM)
(Additional file 2: Figure S2). Since DMC is a more potent
ER stress inducer than celecoxib and does not target
COX-2 (Pyrko et al. 2007; Chuang et al. 2008), these re-
sults suggest that ER stress activation is closely related
to the reduction of cell viability, and subsequently, the
enhancement of TRAIL-induced cytotoxicity in these
cells.
To confirm that the combinatorial effects described
above were correlated with enhanced apoptosis activity,
the effect of DMC on TRAIL-induced caspase cleavage
was further analysed. Figure 4B shows that after 5h
treatment, A172 cells display a significant activation of
the caspases-8, −9, −3 and PARP cleavage when exposed
to rhTRAIL WT alone, and enhanced cleavage whencombined with DMC. Treatment with 100 ng/ml of
rhTRAIL WT and 50 μM DMC resulted in massive cell
death in A172 cells. Notably, DMC alone did not induce
any activation of downstream apoptosis-related proteins,
as indicated by a lack of caspase activation or PARP
cleavage, and in agreement with our earlier observations
using Annexin V staining assays (Figure 3B). Further-
more, acridine orange staining of DMC-treated cells
showed no evidence of nuclear condensation and nu-
clear/cellular fragmentation, as shown after rhTRAIL
WT treatment in A172 cells, but it does appear that
DMC reduces cell proliferation, especially in A172 cells
(Figure 5). Notably, in U87 cells the combined treatment
of rhTRAIL WT with 50 μM DMC led to activation of
the initiator pro-caspase-8 but no subsequent pro-
caspase-9, −3 or PARP cleavage. Treatment of U87 cells
with both TRAIL WT and DMC resulted in the down-
regulation of pro-caspase-3 in this cell line (Figure 4B).
Finally, the effect of combined exposure to rhTRAIL
WT and DMC was also examined in U87-control and
Figure 4 Increased TRAIL sensitivity by DMC is caspase-dependent. (A) Cell viability was assessed after 24h co-treatment with rhTRAIL WT
(0–250 ng/ml) and 0, 25 or 50 μM DMC using a MTS assay. (B) Western blot analysis of A172 (5h) and U87 (24h) cells treated with either rhTRAIL
WT (0, 10 or 100 ng/ml) and/or DMC (0, 25 or 50 μM) for caspase-8, −9, −3 and PARP. β-actin served as a loading control.
van Roosmalen et al. SpringerPlus 2014, 3:495 Page 6 of 12
http://www.springerplus.com/content/3/1/495U87-DR5 cells, with no significant effect of DMC on
TRAIL-sensitivity being observed for these cell lines
(Additional file 3: Figure S3).DMC down-regulates the anti-apoptotic survivin in A172
and U87 cells
Previous studies have reported that ER stress can stimu-
late apoptosis induction not only by up-regulating pro-
apoptotic proteins, such as DR5, but also by down-
regulating anti-apoptotic proteins, such as c-Flip (Chen
et al. 2007; Zhou et al. 2013; Yoon et al. 2013; Martin-
Perez et al. 2012), Bcl-2 (Zhou et al. 2013; Lee et al. 2008;
McCullough et al. 2001) and survivin (Zhou et al. 2013;
Gaiser et al. 2008). Treatment with sub-toxic or toxic con-
centrations of DMC did not affect the level of TRAIL re-
ceptors on the surface of both A172 and U87 cells
(Figure 6A). Interestingly, Western Blot analysis showed
that DMC treatment resulted in a significant down-
regulation of survivin levels in both cell lines (Figure 6B).
Furthermore, c-Flip expression levels were slightly down-
regulated in U87 when treating these cells with DMC. Fi-
nally, DMC treatment did not increase the expression ofDR5 or reduce the expression of the anti-apoptotic pro-
tein Bcl-2.Enhancement of TRAIL sensitivity in A172 cells by
survivin siRNA
In order to determine if down-regulation of survivin by
DMC could explain the increase in TRAIL sensitivity ob-
served in A172 cells, its expression was selectively silenced
using a siRNA approach. Figure 7A shows efficient down-
regulation of survivin upon siRNA transfection, which
resulted in apoptosis activation as indicated by PARP cleav-
age. Interestingly, the addition of only 10 ng/ml rhTRAIL
WT enhanced PARP cleavage in survivin knockdown cells
(Figure 7A), whereas the addition of D269H/E195R resulted
in massive cell death, such that an insufficient amount of
lysate could be prepared. Finally, analysis of cell viability
upon TRAIL treatment in non-transfected, control-siRNA
and survivin-siRNA treated cells indicate that the down-
regulation of survivin slightly increased rhTRAIL WT- and
rhTRAIL D269H/E195R-mediated apoptosis in A172 at
low concentrations, when compared to both untransfected
and control-siRNA treated cells (Figure 7B).
Figure 5 DMC reduces proliferation in GBM cells. Acridine orange staining was used to visualize apoptosis in A172 (A) and U87 (B). Cells
were treated with 0, 10 or 100 ng/ml rhTRAIL WT and 0, 25 or 50 μM DMC. After 24h, cells were stained using acridine orange dye.
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TRAIL is a promising anticancer therapeutic agent that
is able to induce apoptosis in various tumour cells while
leaving normal cells unharmed (Ashkenazi et al. 1999;
Lawrence et al. 2001). Currently, many GBM cells show
resistance to TRAIL-induced apoptosis due to various
reasons, including low expression of DR4 and DR5
(Knight et al. 2001; Kuijlen et al. 2006), the up-
regulation of anti-apoptotic proteins such as c-Flip, Bcl-
2 and survivin (Knight et al. 2001; Kouri et al. 2012;
Song et al. 2003; Xie et al. 2006; Fulda et al. 2002), orthe down-regulation of critical pro-apoptotic proteins
such as caspase-8 and Bak (Knight et al. 2001; Song
et al. 2003; Capper et al. 2009; Qi et al. 2011). Recently,
the use of ER stress inducers, like DMC, have raised
great interest as potential anti-cancer agents and sensi-
tizers for TRAIL-based therapies, since ER stress was
reported to down-regulate important anti-apoptotic pro-
teins, including c-Flip (Chen et al. 2007; Zhou et al.
2013; Yoon et al. 2013; Martin-Perez et al. 2012), Bcl-2
(Zhou et al. 2013; Lee et al. 2008; McCullough et al.
2001) and survivin (Zhou et al. 2013; Gaiser et al. 2008).
Figure 6 DMC mainly down-regulates the anti-apoptotic protein survivin. (A) Flow cytometry analysis was performed after 24h of 0, 25 or
50 μM DMC treatment to measure the cell surface expression of TRAIL receptors in A172 and U87 cells, expressed as the Mean Fluorescence
Intensity (MFI) ratio. Error bars represent S.E.M. of three independent experiments. (B) Western blot analysis of A172 (5h) and U87 (24h) cells
treated with either rhTRAIL WT (0, 10 or 100 ng/ml) and/or DMC (0, 25 or 50 μM). C-Flip, Bcl-2 and survivin protein expression levels were tested.
β-actin served as a loading control. Presented data are representative for at least two independent experiments.
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of DMC in a panel of GBM cells, as well as the potential
of DMC in enhancing TRAIL-induced apoptosis in
TRAIL-resistant and -sensitive GBM cells.
We find that A172 and U87 express predominantly
DR5 but not DR4 on their surface, with different levels
of expression observed between cell lines (Figure 1A).
The DR5-high expressing A172 cells were especiallyFigure 7 Sensitivity of A172 to TRAIL-induced apoptosis is slightly en
survivin siRNA transfected A172 cells treated with or without 10 ng/ml rhTR
survivin down-regulation and apoptosis induction by PARP cleavage. β-act
siRNA were treated with 0–100 ng/ml rhTRAIL WT or rhTRAIL D269H/E195R
corrected for control or survivin knockdown induced cytotoxicity. Presente
and mean cell viability levels ± S.E.M. are shown.sensitive to apoptosis induced by the rhTRAIL variant
D269H/E195R, while U87 cells were resistant to apop-
tosis induction via both DR4 and DR5 (Figure 1B). Inter-
estingly, the ectopic overexpression of DR5 in U87 cells
does not lead to enhancement of TRAIL sensitivity, indi-
cating that lowered surface death receptor levels is not
the main reason for TRAIL resistance in this cell line,
and further suggesting that downstream processeshanced by down-regulation of survivin. (A) Western blot analysis of
AIL WT or rhTRAIL D269H/E195R for 5h. Lysates were tested for
in served as a loading control. (B) A172 cells transfected with survivin
. Cell viability was assessed after 24h using MTS assay. The graphs are
d data are representative for at least three independent experiments
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(Figure 2A-B).
We further studied the impact of ER stress inducer
DMC, alone and in the context of TRAIL-mediated
apoptosis. We demonstrate that DMC is able to effi-
ciently reduce the cell viability of a panel of GBM cells
and induce ER stress as seen by the up-regulation of the
ER stress proteins GRP78 and CHOP in A172 and U87
cells (Figure 3). Although A172 and U87 show a clear
dose-dependent reduction in cell viability upon treat-
ment with DMC, this is not accompanied by an en-
hancement of Annexin V or PI staining in these two cell
lines (Figure 3B), the activation of caspases (Figure 4B)
or the appearance of nuclear condensation (Figure 5), in-
dicating that DMC did not trigger apoptosis or necrosis
in these GBM cells after 24h incubation using the men-
tioned concentrations. However, looking at Figure 5, it
appears that DMC is reducing proliferation rates, espe-
cially in A172 cells.
The combination of rhTRAIL WT or the DR5-specific
variant with middle or high concentrations of DMC re-
sulted in a significant increase in apoptosis induction in
A172, leading to nearly complete apoptosis induction at
very low concentrations of the ligand rhTRAIL when
combined with DMC (Figure 4 and 5). Although the up-
regulation of DR5 (Chen et al. 2007; Zhou et al. 2013;
Yoon et al. 2013; Martin-Perez et al. 2012; Kim et al.
2011; Tian et al. 2011; Lee et al. 2008) or down-
regulation of c-Flip (Chen et al. 2007; Zhou et al. 2013;
Yoon et al. 2013; Martin-Perez et al. 2012), Bcl-2 (Zhou
et al. 2013; Lee et al. 2008; McCullough et al. 2001) or
survivin (Zhou et al. 2013; Gaiser et al. 2008; Pyrko et al.
2006) have been previously described as molecular
mechanisms accountable for the sensitizing effect of ER
stress induction (or DMC treatment on TRAIL-induced
apoptosis), we only detected down-regulation of survivin
in these cell lines upon treatment with DMC (Figure 6).
Survivin down-regulation induced apoptosis in A172
cells and only slightly affected rhTRAIL WT and
D269H/E195R sensitivity in this cell line (Figure 7). The
fact that survivin-mediated knockdown only partially
affects the sensitivity of this cell line towards TRAIL-
induced apoptosis indicate that other mechanisms, per-
haps ER-stress independent, may further contribute to
the synergistic effects observed for TRAIL in combin-
ation with DMC. Furthermore, the depletion of survivin
by siRNA led to the induction of apoptosis in A172,
contrasting to the lack of clear apoptosis-inducing activ-
ity by the ER stress agent DMC.
Recently, Kardosh et al. have assigned the anti-tumour
effect of DMC to the inhibition of cell proliferation
through the down-regulation of cyclins A and B and the
consequent loss of cyclin-dependent kinase activity. In
that report, the authors have demonstrated the dose-dependent down-regulation of cell cycle-regulatory pro-
teins in the presence of 0, 25 and 50 μM of DMC or cel-
ecoxib (Kardosh et al. 2005). A recent study by Ehrhardt
et al. described the increased sensitivity to TRAIL-
induced apoptosis in cell cycle-arrested tumour cells
(Ehrhardt et al. 2013). These findings, combined with
our observation that synergistic effects can be observed
when using DMC in combination with TRAIL in a sub-
set of GBM cells, give us further insight in the pleio-
tropic nature of this class of compounds and their
potential effects in further enhancing or sensitizing can-
cer cells to TRAIL-induced apoptosis.
In contrast to the results obtained for A172 cells,
DMC was not sufficient to circumvent TRAIL-resistance
in U87 and DR5 overexpressing U87 cells, even when
both c-Flip and survivin down-regulation was observed
after treatment with 50 μM DMC. While the combined
treatment of rhTRAIL WT with 50 μM DMC led to a
clear activation of pro-caspase-8, subsequent cleavage of
pro-caspase-9, −3 and PARP could not be detected. In-
triguingly, combination treatment of U87 led to a signifi-
cant reduction in the expression of pro-caspase-3. Yet,
U87 cells remain resistant to TRAIL, likely due to re-
duced pro-caspase-3 expression levels or other persistent
downstream mechanisms of resistance that are in place
in this particular cell line. Although several mechanisms
of caspase-3 down-regulation have been previously de-
scribed (Suzuki et al. 2001; Chen et al. 2003; Mica et al.
2004; Tan et al. 2006), it is currently unclear how the
combination of TRAIL/DMC results in reduction in
pro-caspase-3 expression in this cell line.Conclusions
Our data clearly shows DMC might be a potential anti-
cancer agent for the treatment of GBM, that can further
potentiate TRAIL-induced apoptosis in a subset of
GBM. DMC alone appears to effectively decrease the cell
viability of a panel of GBM cells. Importantly, reduction
of cell viability by 24h treatment with DMC did not lead
to apoptosis or necrosis, but seems be due to reduced
proliferation. We find that the DMC-mediated down-
regulation of survivin partially accounts for the mechan-
ism of TRAIL sensitization in A172 cells. As rhTRAIL
warrants high tumour selectivity and sub-toxic concen-
trations of DMC further sensitize these cancer cells to
TRAIL, it will be important to assess how other cells, es-
pecially primary cells, respond to such combination mo-
dalities. Additionally, the anti-tumorigenic properties of
DMC alone and in the context of co-treatment will re-
quire further in vitro and in vivo studies, especially consid-
ering how effective cancer-specific apoptosis induction
may provide therapeutic opportunities for the treatment
of GBM as well as many other cancers.
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Cell lines and chemicals
Human glioblastoma cell lines A172, U87, SNB75 and
U251 were obtained from the American Type Culture
Collection (ATCC). Cells were cultured in DMEM with
4.5 g/L D-glucose (Gibco, Life Technologies) supple-
mented with 10% foetal calf serum, 100 units/mL peni-
cillin and 100 μg/ml streptomycin in a humidified
incubator at 37°C containing 5% CO2. 2,5-Dimethyl-cel-
ecoxib (DMC) was produced as described earlier
(Kardosh et al. 2005; Ahlstrom et al. 2007). Celecoxib
(CXB) was purchased from Key Organics. DMC and
CXB were both dissolved in DMSO; the control with
only solvent (DMSO) showed no toxicity. RhTRAIL
wild-type (WT), DR4-specific TRAIL variant 4C7 and
DR5-specific TRAIL variant D269H/E195R (amino acids
114–281) were constructed and produced as described
earlier (van der Sloot et al. 2006; Reis et al. 2010).
Cell viability and apoptosis assays
Cell viability was measured using the MTS assay, a
colorimetric method in which viable cells reduce 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) to a formazan product.
Cells were seeded in triplicate in 96-well plates at a cell
density of 10,000 cells/well. After 24h, cells were treated
for 24h with concentrations ranging from 0 to 250 ng/mL
of rhTRAIL WT or D269H/E195R and/or 0 to 100 μM
DMC in a final volume of 0.15-0.2 mL; reagents and li-
gands were serially diluted in cell culture medium. Cells
were incubated with the MTS reagent according to the
manufacturer’s instructions (G3581, Promega). Cell via-
bility was determined by measuring the absorption at
492 nm on a microplate reader (Thermo Labsystems).
Apoptosis induction was measured using Annexin V-
FITC and propidium iodide (PI) staining and quantified
by flow cytometry. Cells were seeded in 6-well plates 24
h prior to treatment. The next day, cells were treated
for 24h with 0, 25 or 50 μM DMC. After treatment,
cells were harvested and washed with calcium buffer
(10.9 μM HEPES, 140 μM NaCl, 2.5 μM CaCl2). Cell
pellets were resuspended in 60 μL calcium buffer com-
plemented with 5 μL Annexin V-FITC (IQP-120F, IQ
Products) and incubated for 20 minutes on ice. Cells
were washed and resuspended in 0.5 μg/mL PI (P4170,
Sigma Aldrich) diluted in calcium buffer and left on ice
until analysis. Cells were analysed using a FACSCalibur
flow cytometer (BD).
Visualisation of apoptosis was accomplished using ac-
ridine orange. Cells were seeded in triplicate in 96-well
plates with 10,000 cells/well 24h prior to treatment.
Treatment consisted of rhTRAIL WT (0, 10 or 100 ng/mL),
with or without DMC (0, 25 or 50 μM) as indicated.
After 24h incubation, cells were stained with 2 μL/well10x diluted 1 mg/ml acridine orange solution and incu-
bated for 10 minutes. Plates were spun down for 10 mi-
nutes at 900 rpm. Fluorescence microscopy was used to
determine the presence of apoptotic bodies and/or chro-
matin condensation.Western blotting
GBM cells were seeded in T25 culture flasks at a density
of 750,000 cells/flask 24h prior to treatment. For
TRAIL-induced apoptosis, A172 cells were treated for
5h and U87 for 24h, since apoptosis is induced quickly
in A172 cells. Cells were treated with rhTRAIL WT (0,
10 or 100 ng/mL), with or without DMC (0, 25 or 50
μM). After treatment, cells were harvested and lysed
using the M-PER Mammalian Protein Extraction Re-
agent (PIERCE, Thermo Scientific) with additional Pro-
tease Inhibitor Cocktail, EDTA-Free (100x; Thermo
Scientific). Protein concentrations were determined
using a Bradford assay (Bio-Rad Laboratories). Equal
amounts of protein for each sample were loaded per lane
on pre-cast 4-12% SDS-PAGE gels (Invitrogen) and
transferred onto Immobilon-FL PVDF 0.45 μm mem-
branes (Millipore). Subsequently, the membranes were
blocked for 1 h at room temperature in blocking buffer
(Rockland). Western Blot membranes were probed over-
night at 4°C. The following primary antibodies were
used: caspase-3 (9662, 9661), caspase-8 (9746), caspase-9
(9501, 9508), c-Flip (8510), CHOP (2895), PARP (9542)
(Cell Signaling), COX-2 (160112, Cayman Chemical),
GRP78 (sc-13968, Santa Cruz) and survivin (AF886,
R&D Systems). Goat-α-mouse-IRDye (800CW; 926–
32210 and 680; #926-32220) or goat-α-mouse-IRDye
(800CW; 926–32211 and 680; #926-32221) secondary
antibodies (Westburg) were used for detection using a
LI-COR Odyssey Infrared Imaging System (Westburg).
Membranes were probed with anti-β-actin (0869100,
MP Biomedicals) to confirm equal loading.TRAIL receptor expression analysis
GBM cells were harvested and washed with standard
buffer (PBS/1% BSA). TRAIL receptor cell surface ex-
pression was determined using 10 μg/mL TRAIL-R1
(ALX-804-297), TRAIL-R2 (ALX-804-298), TRAIL-R3
(ALX-804-344), TRAIL-R4 (ALX-804-299) (Alexis Bio-
chemicals, Enzo Life Sciences.), DR5-01-1 (EXB-11-461,
Exbio) or negative control mouse IgG1 (X0931, DAKO).
Cells were incubated with primary antibodies for 1 h.
Subsequently, the cells were washed and incubated for 1 h
with R-phycoerythrin (PE) conjugated goat anti-mouse
antibody (1010–09, Southern Biotech) or Alexa Fluor 488
conjugated goat anti-mouse antibody (A-11001, Invitro-
gen). Receptor cell surface expression was analysed using
a FACSCalibur flow cytometer (BD).
van Roosmalen et al. SpringerPlus 2014, 3:495 Page 11 of 12
http://www.springerplus.com/content/3/1/495Retroviral-based DR5 overexpresssion
DR5-TV1 was amplified from a plasmid (kindly provided
by MSD) using forward (5′-agatctatggaacaacggggacag
aacg-3′) and reverse (5′-cgcgaattcttaggacatggcagagt-3′)
primers containing BglII and EcoRI restriction sites. The
PCR product was cloned into pMSCV-tdTomato, a
retrovirus expression system (kindly provided by prof. J.J.
Schuringa). For the packaging of the retroviral particles,
2 × 106 HEK293 cells were plated in 94.0 mm cell cul-
ture dishes. The next day, cells were transfected with ei-
ther pMSCV-tdTomato vector expressing DR5-TV1 or
an empty vector, using CaCl2. After 24h, the medium
containing virus particles was harvested, filtered and
added to U87 cells, which were plated the day before at
a density of 0.25 × 106 U87 cells in wells of a 6-wells
plate. The U87 cells were exposed to the viral particles
for 48 h after which the virus was removed and fresh
medium was added. Mixed populations of U87-empty or
U87-DR5 cells were cultured in DMEM with 4.5 g/L D-
glucose (Gibco, Life Technologies) supplemented with
10% foetal calf serum, 100 units/mL penicillin, and 100
μg/ml streptomycin in a humidified incubator at 37°C
containing 5% CO2. U87 transduced cells, containing
constructs encoding tdTomato, were sorted using a
fluorescent activated cell sorter.
RNA interference
A172 cells were seeded in 6-wells plates at a density of
200,000 cells/well. The next day, the subconfluent cul-
tures were incubated with unsupplemented Optimem
medium (Gibco, Life Technologies) and transfected with
133 nM survivin (sc-29499, Santa Cruz) or negative con-
trol small interfering RNA (siRNA) (SR-CL000-005,
Eurogentec) using Oligofectamine Transfection Reagent
(12252–011, Invitrogen) according to the manufacturer’s
protocol. 24h after siRNA transfection, cells were seeded
and treated as indicated for MTS assays (24h treatment)
or Western blot analysis (5h treatment).Additional files
Additional file 1: Figure S1. A172 and U87 cells are less sensitive to
celecoxib when compared to DMC. Cell viability was assessed after 24h
exposure of A172 (A) or U87 (B) to 0–100 μM of CXB or DMC using a
MTS assay. Error bars represent S.E.M. of three independent experiments.
Additional file 2: Figure S2. DMC is more potent in reducing cell
viability when combined with TRAIL than celecoxib. Cell viability was
assessed after 24h co-treatment of A172 (A) or U87 (B) with rhTRAIL WT
(0–250 ng/ml) and 0, 25 or 50 μM celecoxib (CXB) or DMC using MTS
assays. Error bars represent S.E.M. of three independent experiments.
Additional file 3: Figure S3. DR5 overexpression in U87 cells did not
enhance sensitivity to TRAIL in combination with DMC. Viability was
assessed after 24h co-treatment of U87-control (A) or U87-DR5 (B) with
0–1000 ng/ml rhTRAIL WT and 0, 25 or 50 μM DMC using MTS assays.
Presented data are representative for three independent experiments and
mean cell viability levels ± S.E.M. are shown.Abbreviations
DMC: 2,5-dimethyl-celecoxib; TRAIL: TNF-related apoptosis-inducing ligand;
GBM: Glioblastoma multiforme; ER stress: Endoplasmic reticulum stress;
rhTRAIL (WT): Recombinant human TRAIL (wild type); DR4/5: Death receptor
4/5; DISC: Death-inducing signalling complex; FADD: FAS-associated death
domain; tBid: Truncated Bid; COX-2: Cyclooxygenase-2; NSAID: Non-steroidal
anti-inflammatory drug; SERCA: Sarcoplasmic/ER calcium ATPase; ERS: ER
stress response; GRP78: Glucose-regulated protein 78; CHOP: CCAAT/-
enhancer-binding protein homologous protein; ATCC: American type culture
collection; PI: Propidium iodide; M-PER: Mammalian protein extraction
reagent; PE: R-phycoerythrin; siRNA: Small interfering RNA; MFI: Mean
fluorescence intensity.
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